Regeneron Pharmaceuticals Management
Management criteria checks 4/4
Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.83 years. total yearly compensation is $8.18M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 2.23% of the company’s shares, worth $1.78B. The average tenure of the management team and the board of directors is 7.2 years and 17.9 years respectively.
Key information
Leonard Schleifer
Chief executive officer
US$8.2m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 36.8yrs |
| CEO ownership | 2.2% |
| Management average tenure | 7.2yrs |
| Board average tenure | 17.9yrs |
Recent management updates
Recent updates
Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09
Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
| Sep 30 2019 | n/a | n/a | US$2b |
| Jun 30 2019 | n/a | n/a | US$2b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$27m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$1b |
| Dec 31 2017 | US$27m | US$1m | US$1b |
Compensation vs Market: Leonard's total compensation ($USD8.18M) is below average for companies of similar size in the US market ($USD12.73M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard Schleifer (71 yo)
36.8yrs
Tenure
US$8,184,338
Compensation
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 36.8yrs | US$8.18m | 2.23% $ 1.8b | |
| Co-Founder | 23.8yrs | US$7.76m | 1.07% $ 859.0m | |
| Executive Vice President of Research | 5.8yrs | US$8.43m | 0.048% $ 38.3m | |
| Executive VP and GM of Industrial Operations & Product Supply | 16.6yrs | US$8.76m | 0.031% $ 25.2m | |
| Senior VP of Finance & CFO | less than a year | no data | 0.017% $ 14.0m | |
| Senior Vice President of Quality Assurance & Operations | 4.8yrs | no data | no data | |
| Senior VP of IT & Chief Information Officer | 3.8yrs | no data | no data | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | no data | no data | |
| Executive VP | 13.2yrs | US$7.13m | 0.036% $ 28.5m | |
| Senior VP & Chief Compliance Officer | 1.8yrs | no data | no data | |
| Senior Vice President of Corporate Affairs | no data | no data | no data | |
| Executive Vice President of Human Resources | 8.6yrs | no data | no data |
7.2yrs
Average Tenure
64.5yo
Average Age
Experienced Management: REGN's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 36.8yrs | US$8.18m | 2.23% $ 1.8b | |
| Co-Founder | 23.8yrs | US$7.76m | 1.07% $ 859.0m | |
| Lead Independent Director | 14yrs | US$748.01k | 0.00073% $ 584.8k | |
| Independent Director | 21.8yrs | US$724.99k | 0.016% $ 13.1m | |
| Independent Director | 33.4yrs | US$728.99k | 0.012% $ 9.3m | |
| Independent Director | 33.4yrs | US$709.99k | 0.0046% $ 3.7m | |
| Independent Director | 36.8yrs | US$724.99k | 0.026% $ 21.2m | |
| Independent Director | 7.8yrs | US$704.99k | 0.000010% $ 8.0k | |
| Independent Director | 2.1yrs | US$247.79k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$714.99k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$709.99k | 0.0013% $ 1.0m | |
| Independent Director | 1.2yrs | US$1.03m | 0% $ 0 |
17.9yrs
Average Tenure
71yo
Average Age
Experienced Board: REGN's board of directors are seasoned and experienced ( 17.9 years average tenure).